Interplay between Basic Residues of Hepatitis C Virus Glycoprotein E2 with Vi ral Receptors Neutralizing Antibodies and Lipoproteins. by Koutsoudakis, George et al.
Interplay between Basic Residues of Hepatitis C Virus
Glycoprotein E2 with Viral Receptors, Neutralizing
Antibodies and Lipoproteins
George Koutsoudakis*., Jakub Dragun., Sofia Pe´rez-del-Pulgar, Mairene Coto-Llerena, Laura Mensa,
Gonzalo Crespo, Patricia Gonza´lez, Miquel Navasa, Xavier Forns
Liver Unit, Hospital Clı´nic, Institut D’Investigacions Biome`dics August Pi i Sunyer, Centro de Investigacio´n Biome´dica en Red de Enfermedades Hepa´ticas y Digestivas,
Barcelona, Spain
Abstract
Positively-charged amino acids are located at specific positions in the envelope glycoprotein E2 of the hepatitis C virus
(HCV): two histidines (H) and four arginines (R) in two conserved WHY and one RGERCDLEDRDR motifs, respectively.
Additionally, the E2 hypervariable region 1 (HVR1) is rich in basic amino acids. To investigate the role(s) of these residues in
HCV entry, we subjected to comparative infection and sedimentation analysis cell culture-produced (HCVcc, genotype 2a)
wild type virus, a panel of alanine single-site mutants and a HVR1-deletion variant. Initially, we analyzed the effects of these
mutations on E2-heparan sulfate (HS) interactions. The positive milieu of the HVR1, formulated by its basic amino acids (key
residues the conserved H386 and R408), and the two highly conserved basic residues H488 and R648 contributed to E2-HS
interactions. Mutations in these residues did not alter the HCVcc-CD81 entry, but they modified the HCVcc-scavenger
receptor class B type I (SR-BI) dependent entry and the neutralization by anti-E2 or patients IgG. Finally, separation by
density gradients revealed that mutant viruses abolished partially or completely the infectivity of low density particles,
which are believed to be associated with lipoproteins. This study shows that there exists a complex interplay between the
basic amino acids located in HVR1 and other conserved E2 motifs with the HS, the SR-BI, and neutralizing antibodies and
suggests that HCV-associated lipoproteins are implicated in these interactions.
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Introduction
Hepatitis C virus (HCV) is a small enveloped positive-strand
RNA virus that belongs to the Flaviviridae family [1]. HCV
possesses two envelope glycoproteins (gps), designated E1 and E2,
which drive the viral component during the infection of the
hepatic cells [2]. Initial attachment of HCV on hepatocytes occurs
via binding of E2 with highly sulfated heparan sulfate (HS) [3,4].
These unspecific interactions aid the concentration of HCV on the
surface of hepatic cells for further interactions with the subsequent
specific receptors. CD81 has been the first molecule identified to
interact with a soluble truncated form of E2 [5]. Several amino
acids critical for E2-CD81 interaction have been identified
throughout the CD81 large extracellular loop and E2 by
biochemical assays [6,7]. Recently, the development of the HCV
pseudoparticle (HCVpp) [8,9] and the HCV cell-culture (HCVcc)
systems [10,11,12] has provided valuable tools to study HCV-
receptors interactions in a more natural context.
Scavenger receptor class B type I (SR-BI) was identified as a
potential HCV receptor via its extracellular loop interactions with
E2 [13]. Recent data, though, are controversial. SR-BI natural
ligands involve a variety of lipoproteins (HDL, LDL, oxidized
LDL) which can modulate HCV infection: HDL is able to
enhance HCVpp and HCVcc infections [14,15] whereas oxidized
LDL acts in an inhibitory way [16]. Interestingly, by using serum-
derived HCV, it has been suggested that the virus associated
ApoB-containing lipoproteins rather than the E2 interact with SR-
BI [17]. Finally, Grove et al., identified a residue in E2 (G451) that
determined SR-BI dependency and sensitivity to neutralizing
antibodies [18].
HCV circulates in the blood in association with LDL and
VLDL [19], thus constituting the so-called lipo-viral particles
(LVPs). LVPs exhibit low densities (#1.08 g/ml) and are highly
infectious. Increasing evidence arises from studies demonstrating
that HDL and likely other HCV-associated lipoproteins promote
HCV entry via receptors-lipoproteins interactions and reduce the
neutralizing effect of anti-HCV antibodies [14,20,21]. The
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hypervariable region 1 (HVR1) of E2 has been implicated in these
mechanisms [22]
The envelope gps of HCV exhibit a high degree of genetic
heterogeneity, especially in the HVR1 of E2 [23]. However,
positively-charged amino acids appear to be predominant in
several HVR1 positions and may contribute to virus entry [24].
Moreover, basic amino acids at conserved regions along E2 appear
to play a role in E2-HS binding in vitro. These regions have been
characterized as putative glycosaminoglycan (GAG)-binding sites
and are composed of the following motifs: 484PYCWHYAP491,
610DYPYRLWHYPC620 and 648RGERCDLEDRDR659. Basic
amino acids H488, H617, R648, R651, R657 and R659 are known
to play a major role in this type of binding [25].
The aim of this study was to analyze the role(s) played by basic
amino acids located in HVR1, as well as in the putative GAG-
binding sites found in E2 with respect to their interactions with
viral receptors during HCV entry. Unravelling the complex
interactions between HCV envelope glycoproteins and the various
cellular receptors could help us not only to fully understand the
highly orchestrated events that occur during HCV entry, but also
to design specific and highly potent anti-HCV therapeutic
strategies.
Materials and Methods
Ethics statement
The Investigation and Ethics Committee of Hospital Clinic
Barcelona approved our protocol including the use of human
samples, and conformed to the ethical guidelines of the 1975
Declaration of Helsinki. Written informed consent was obtained
from all patients included in this study.
Cell lines
Huh-7.5 cells were grown in Dulbecco’s modified eagle medium
(DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, non-essential amino acids, and
100 U/ml of streptomycin/penicillin (DMEM complete). Cells
were grown in 37uC 5% CO2 in a water-jacketed incubator.
Antibodies
A detailed list of antibodies used in this study is given in
Information S1.
IgG isolation from patient or normal sera
Patient or normal blood (HCV+ or HCV2, respectively) was
collected in a VacutainerH Rapid Serum Tube (Becton Dickinson,
Franklin Lakes, NJ) and sera were separated after centrifugation at
1,7006g for 10 min. 150 ml serum was used for total IgG isolation
by using a protein A HP SpinTrapTM (GE Healthcare, Waukesha,
WI) according to the manufacturer’s instructions.
Site-directed mutagenesis
Alanine mutants were introduced into the HC-J6CH E1E2
expression plasmid (pcDNA3.1-DcE1E2-J6CH) using a PCR-
based GENEARTH Site-Directed Mutagenesis System (Invitrogen
Eugene, OR). A detailed description of this method is available in
the Information S1 section.
In vitro transcription, electroporation of HCV RNAs,
generation of HCVcc stocks, luciferase assays,
quantification of HCV core protein, RT-qPCR and
determination of virus titers in cell culture supernatants
These methods were employed as previously described [26].
Preparation of cell lysates, PAGE and Western blot
Huh-7.5 cells were electroporated with Jc1 WT or mutant
RNAs. 72 h post electroporation, cells were washed with PBS and
lysed on ice with lysis buffer (0.5% Triton X-100 in 50 mM Tris-
HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA) supplemented with
protease inhibitor (1 mM PMSF) for 30 min. Cell lysates were
clarified by centrifugation (30 min 20,0006 g) at 4uC. Total
protein in the lysates was quantified with a Lowry protein assay
and equal protein amounts (30 mg) for each sample were diluted
into sample buffer (160 mM Tris, pH 6.7, 2% SDS, 10% glycerol,
0.004% bromophenol blue, 50 mM DTT). Samples were heated
at 70uC for 10 min and then loaded onto a NuPAGE, Novex 4–
12%, Bis-Tris Midi gel (Invitrogen, Eugene, OR). Following
electrophoresis, proteins were transferred onto an Immobilon-P
PVDF membrane (Millipore, Billerica, MA) using semi-dry blotter
unit (Sigma-Aldrich, St. Louis, MO). Membranes were blocked
with 5% non-fat milk in PBS, 0.05% Tween-20 (blocking solution)
for 1 h at RT. Incubation with the primary antibody anti-E2
(BDI167, 0.5 mg/ml) or anti-b-actin (0.01 mg/ml) was performed
in blocking solution overnight at 4uC. Blots were washed five times
for 10 min in washing solution (0.05% Tween-20 in PBS),
incubated for 1 h with anti-mouse HRP-conjugated secondary
antibody in blocking solution (1:5,000, Sigma-Aldrich, St. Louis,
MO), and washed as described above. Antibody-protein complex-
es were detected using the SuperSignalH West Femto Maximum
Sensitivity Substrate Kit (Thermo Fischer Scientific Inc., MA) with
a LAS4000 Image acquisition system (GE Healthcare Life
Sciences, Uppsala, Sweden).
In the case of ApoE analysis in density fractions, 10 ml of each
fraction were incubated with 2.5 ml sample buffer, loaded onto a
NuPAGE gel as described previously, electrophorized and
transferred to a PVDF membrane. Immobilized ApoE proteins
were detected with the anti-ApoE (Abnova, PAB9972, 0.1 mg/ml).
E2 conformational antibody immunoprecipitation
500 mg of each cell lysate described above were incubated with
1 mg of AR3A conformational antibody overnight at 4uC with
gentle agitation. Protein G Sepharose 4 Fast Flow beads (GE
Healthcare Life Sciences, Uppsala, Sweden) were rinsed with lysis
buffer and 40 ml of beads was added to each AR3A-antibody pre-
treated cell lysate. Sepharose beads-lysates-antibodies complexes
were incubated for 3 h with gentle rocking at 4uC. Complexes
were washed 3 times with lysis buffer. Finally, beads were spun at
full-speed and supernatants were discarded. 25 ml SDS-PAGE
loading buffer was added to the beads, and samples were boiled for
10 min at 70uC and were then analyzed by PAGE and western
blotting as described above. Bands density quantification was
performed by the ImageJ Software.
HCVcc infections and entry inhibitions
HCVcc infections were employed as previously described [4]
with normalized HCVcc-containing supernatants (1,000 fmol/l
core). To facilitate quantification of infection, we utilized the
bicistronic Jc1 luciferase reporter construct Luc-Jc1 in our
infection analyses. Huh-7.5 cells were seeded in 12 well plates,
86104 cells/well, 18 h prior to inoculation with normalized
HCVcc-containing supernatants. In the case of heparin (heparin
sodium salt from porcine intestinal mucosa, Calbiochem, Darm-
stadt, Germany), chondroitin (chondroitin sulfate C sodium salt
from shark cartilage, Sigma-Aldrich, St. Louis, MO), AR3A or
patient IgG neutralizations, GAGs or antibodies were pre-
incubated with HCVcc-containing supernatants for 1 h prior to
inoculation, at RT with agitation. Anti-CD81 or anti-SR-BI
antibodies were added directly to supernatants simultaneously to
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inoculations. Infections were maintained for 6 h at 37uC 5% CO2
in a water-jacketed incubator with gentle rocking. Cells were lysed
72 h post infection and luciferase activity was measured. Infections
were performed always in duplicate wells measured in duplicates
(n = 4). Results are given as percentage relative to control
infections as follows: heparin relative to chondroitin, mouse mAbs
relative to mouse IgG1 isotype control, human polyclonal and
mAbs relative to normal human IgG, rat polyclonals relative to
normal rat polyclonal IgG and goat polyclonal to goat normal
serum control.
RNA Interference Assay
Commercially available siRNA pools targeting SR-BI as well as
control nontargeting siRNAs were purchased from Novus
biologicals (Littleton, CO). Huh-7.5 cells in each well of a 12-
well cell culture plate were transfected with 50 nM of each siRNA
using INTERFERinTM (Polyplus-transfection SA, Illkrich, France)
following the manufacturer’s protocol. Silencing of SR-BI
expression was assessed by flow cytometry 48 hours after
transfection as described in Information S1. 48 hours after
transfection, cells were incubated with HCVcc, and HCV
infection was assessed as described previously.
Density gradient fractionation
Density gradient centrifugation was performed as has been
previously described [27]. Briefly, viruses were separated by
overnight centrifugation through a 0% to 40% iodixanol step
gradient at 154,0006g in a SW41-T1 swing-out rotor at 4uC using
a Sorvall Ultra WX100 centrifuge and 12 fractions of 1 ml were
collected from the top.
Statistical analyses
The results are presented as means 6 standard deviation (SD).
The statistical comparison between two groups was made by an
unpaired-t test. *p value,0.05, **p value,0.01 and ***p
value,0.001 were considered to indicate a significant difference.
Results
Analyses of GAG-binding sites and basic residues in E2
sequences
Our experiments were performed in the context of genotype 2a
(Jc1 chimera [28], HC-J6CH E2, Acc. No. AF177036) HCVcc
virus. The prototype E2 sequence (H77 isolate, accession Number
AF009606) contains 363 amino acids. However, HC-J6CH E2
contains 367 amino acids. To simplify our analyses, amino acid
numbers refer to positions in the polyprotein sequence of the H77
prototype isolate.
The HC-J6CH isolate contains five basic amino acids in the
HVR1: R384, H386, R398, R408 and K410. Additionally, it contains
the H and R conserved residues in the putative GAG-binding sites
mentioned in the Introduction. Figure 1A depicts the scheme of an
E2 protein, indicating the HVR1, 2 and 3 regions, the putative
GAG-binding sites and sites for N glycosylation.
To assess the conservation of those basic residues between the
HC-J6CH E2 proteins and the natural E2 variants, we analyzed
the alignment of full-length E2 proteins, available in the European
HCV database (http://euhcvdb.ibcp.fr/euHCVdb/). The align-
ment contained 2073 full-length E2. We calculated the frequencies
of all basic amino acids (H, K, or R) at these positions (Fig. 1B).
The basic residues at positions 384 and 398 presented a low
frequency (6.7 and 7.5%, respectively). Nonetheless, those at
positions 386, 408, and 410 occurred at higher frequencies (57.0,
54.4 and 34.5%, respectively) with H, K, and K being the
predominant amino acids found at each position, respectively.
Finally, H488, H617, R648, R651, R657 and R659 were almost
completely conserved.
Generation of E2 glycoprotein mutants
A panel of point alanine site-directed mutants was generated
and divided into 2 groups: Group A referred to mutants relevant
to the HVR1 while group B contained mutants at the putative
GAG-binding sites. To expand our study in the HVR1, we
generated a mutant E2 possessing an alanine substitution in all
basic amino acids of the HVR1 (‘‘basic-’’ mutant), as well as a
deletion mutant (DHVR1). Finally, by introducing an alanine at
position 369 and simultaneously mutating the K370 into an
alanine, the a-helix of the E1 transmembrane (TM) domain was
destabilized, thereby affecting E1E2 heterodimerization (E1AA
mutant) [29]. As this mutant causes E1E2 aggregation and
degradation, it served as a negative control. Table 1 summarizes
the E2 mutants.
Adequate expression of the various E2 mutants was examined
by Western blot analysis in lysates derived post-electroporation
from Huh-7.5 cells with WT or mutants. When probed with anti-
E2 antibody, a band of ,68 kDa was detected, which corre-
sponded to the size of the HCV E2 protein (Fig. 2A). Lysates from
electroporated cells with a HCV subgenomic replicon (SGR [30]),
that does not contain glycoproteins, were used to control anti-E2
specificity. Overall, neither the alanine mutations nor the HVR1
deletion markedly affected E2 protein expression.
Next, we investigated whether any of these alanine substitutions
had any effect on E2 conformation. E2 conformation affects
proper E1E2 heterodimerization, which is essential in mediating
HCV infectivity [31]. To this end, E2 present in the Huh-7.5 cell
lysates was pulled down with a conformational anti-E2 antibody
[32]. Immunocomplexes were analyzed by western blot for the
presence of E2 using monoclonal anti-E2 antibodies (Fig. 2B).
Group A mutants (except DHVR1) did not markedly affect E2
conformation, according to the amount of E2 immunoprecipitated
by this method. For the group B mutants, only mutants R648A
and R651A permitted sufficient E2 detection by immunoprecip-
itation while the H488A, H617A, R657A and R549A mutations
almost completely abrogated the E2 conformation.
Effect of E2 alanine substitutions on infectivity and
heparin neutralization of HCVcc
Next, we tested whether alanine substitutions had any effect on
HCV replication or infectivity. The mutations did not have any
effect on replication (Fig. S1A). The results of our infectivity
experiments are summarized in Figure 3A. Group A point
mutants (R384A, H386A, R398A, K410A) either did not present
any or had a moderate effect on infectivity while mutations of all
basic amino acids (basic-) or deletion of HVR1 (DHVR1) lead to
an infectivity reduction greater than 80%, in comparison to WT
virus. For the group B mutants, only H488A, R648A and R651A
mutants released infectious virus accompanied by a significant loss
of infectivity. These results are in line with the core release in the
supernatant of electroporated cells (Fig. 3A) and they also correlate
well with the E2 conformation data (experimental data in Fig. 2B
and quantification analysis in Fig. 3A) It is worth noting that
mutants did not change the amount of secreted infectious virus
relative to total infectious virus; although core protein secretion
was affected by those mutants as deduced by core supernatant
quantification (Fig. 3A). The amount of extracellular infectivity,
relative to total infectivity, remained ,90% (Fig. S1B) for those
mutants that secreted viruses (Fig. 3A).
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Figure 1. HCV E2 glycoprotein contains conserved basic residues in different regions. (A) Scheme of E2 putative GAG-binding sites and
other regions important for entry and for proper protein folding. Amino acid numbers refer to positions in the polyprotein sequence of the H77
prototype isolate. N: glycosylation sites, HVR1, 2, 3: hyper-variable region 1, 2, 3, TM: transmembrane domain. (B) Frequency of basic residues at the
positions analyzed in this study. The height of the box in each bar indicates the frequency of histidine (H, white box), lysine (K, light grey box) and
arginine (R, dark grey box). The frequency of the basic residues at each position was calculated by dividing the number of basic residues by the total
number of sequences (2073 sequences) and is expressed as a percentage.
doi:10.1371/journal.pone.0052651.g001
Table 1. Mutations of conserved basic amino acids of HCV E2 glycoprotein.
Mutations Isolate HC-J6CH
aa position Amino acid level Nucleotide level
Group A 384 R/A CGC/GCC
386 H/A CAT/GCT
398 R/A CGC/GCC
408 R/A AGG/GCG
410 K/A AAA/GCA
basic- R/A, H/A, R/A, R/A, K/A CGC/GCC, CAT/GCT, CGC/GCC, AGG/GCG,
AAA/GCA
DHVR1 D27 aaa D81 ntb
Group B 488 H/A CAC/GCC
617 H/A CAT/GCT
648 R/A CGT/GCT
651 R/A CGT/GCT
657 R/A AGA/GCA
659 R/A AGA/GCA
E1AA 369, 370 A insertion, K/A GCG insertion, AAG/GCA
aDeletion of 27 aa from the N-terminal part of the E2 protein.
bDeletion of 81 nt from the 59 terminus of the E2 gene.
doi:10.1371/journal.pone.0052651.t001
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To determine the role of alanine mutants in E2-HS binding, we
performed a series of Huh-7.5 cell infections, in the presence of
chondroitin sulfate, which served as a non-antagonist to E2-HS
interaction, or in the presence of heparin, which is known to be a
strong antagonist [4]. Figure 3B summarizes our heparin
inhibition results. H386A and R408A presented a total resistance
to heparin inhibition while basic-, DHVR1, H488A and R648A
mutations exhibited a less resistant phenotype to heparin. As the
mutants E1AA, H617A, R657A and R659A did not produce
infectious virus either extra- or intra-cellularly (Fig. S1B) infection
experiments were not applicable (NA).
HCV particles are associated with the apolipoprotein E (ApoE)
and possible other apolipoproteins [33]. Since ApoE can also bind
to HS [34], we performed neutralization experiments using an
anti-ApoE antibody and the previous identified heparin-resistant
mutants (H386A, R408A, basic-, DHVR1, H488A and R648A).
As shown in Figure 3C and 3D, a similar dose-dependent
inhibition of infection was observed for WT and mutant viruses
when HCVcc particles were pre-incubated with the anti-ApoE
antibodies.
Basic residues of E2 play a role in SR-BI binding
To investigate the impact of the previously identified mutations
on E2-CD81 interactions we exploited the ability of two anti-
CD81 antibodies (clone JS-81 and clone 1D6) to inhibit WT or
mutant infections. 1D6 inhibits E2-CD81 binding, whereas JS-81
may inhibit post-binding steps such as receptor oligomerization
[35]. Figure 4A–D shows that all viruses presented a similar dose-
dependent inhibition to both anti-CD81 antibodies.
Similar inhibition studies were done with two anti-SR-BI
antibodies: the monoclonal C167 [36] and polyclonal IgG specific
to SR-BI [37]. The basic- mutant presented a resistant phenotype
to the anti-SR-BI antibody C167 (Fig. 5A), while the WT virus
presented a dose-dependent inhibition (Fig. 5B). Notably, H386A
and R408A mutants presented a partially resistant phenotype.
Interestingly, the DHVR1 mutant remained sensitive to anti-SR-
BI neutralization. Some degree of resistance was also observed for
the H488A mutant, albeit at low anti-SR-BI concentrations.
Similar results were obtained with the polyclonal anti-SR-BI IgG.
However, the inhibition effect produced by those polyclonal
antibodies was less potent than that obtained by the monoclonal
C167 (Fig. S2).
To further analyze the role of SR-BI in WT and mutants entry,
endogenous expression of SR-BI was silenced transiently with SR-
BI-specific siRNAs prior to virus infection. SR-BI-specific siRNAs
knocked down SR-BI endogenous expression by ,60% (Fig. S3).
Strikingly, the si-RNA-mediated knockdown of SR-BI did not
affect basic- mutant entry while WT entry was inhibited more than
70% (Fig. 5C). Significantly, DHVR1 entry was also inhibited by
SR-BI knock-down. Finally, we found partial entry inhibition for
the mutants H386A, R408A and H488A which is in line with the
neutralization studies with the anti-SR-BI antibodies.
Basic residues of E2 protect HCV against neutralization
by anti-E2 monoclonal and patient- derived IgG
To examine the neutralizing potential of the conformational
anti-E2 AR3A antibody [32], we performed infections using pre-
incubated viruses with various AR3A doses (Fig. 6A and 6B). This
anti-E2 antibody exhibited ,70% neutralization to the WT
viruses at 5 mg/ml. Lower doses presented a ,10–20% neutral-
ization. However, basic-, H386A, and R408A mutants exhibited
more than ,95% neutralization at the higher doses, whereas
basic- and R408A mutants presented a similar phenotype at the
lower doses as well. Lastly, DHVR1 also presented increased
sensitivity to anti-E2 neutralization. In contrast, the H488A
mutant presented some resistance to this anti-E2 antibody. Similar
results were obtained when viruses were pre-incubated with
different amounts of polyclonal IgG derived by 2 chronic genotype
1b HCV patients [38] (Fig. 6C and 6D for patient 1, data not
shown for patient 2), suggesting that basic amino acids protect
conserved viral cross-neutralizing epitopes.
Alanine mutants of basic residues of E2 affect HCVcc
buoyant density
To assess whether alanine mutants modulate the relationship
between HCV and lipids or lipoproteins, we compared the
buoyant density between WT and alanine mutants. Similar to
previous studies [22], WT viruses presented a broad infectivity
spectrum, ranging from 1.02 to 1.18 g/ml (Fig. 7A). The low-
density viruses represented the HCV-lipoprotein complexes, and
Figure 2. Expression and conformation analysis of HCV E2 glycoprotein in cell lysates. (A) Expression analysis of HC-J6CH E2 protein by
anti-E2 Western blot (B) E2 conformation analysis by E2 immunoprecipitation, as well as subsequent E2 detection by Western blot. b-actin detection
was used as a loading control, while cell lysates from cells electroporated with JFH1 subgenomic replicons (SGR) were used as a negative control in
both Western blot and immunoprecipitation experiments.
doi:10.1371/journal.pone.0052651.g002
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the infectivity peak occurred at ,1.10 g/ml. HCV RNA (Fig. 7A)
and core analysis (Fig. S4A) of the distinct HCV populations also
confirmed previous results [22].
H386A, R408A, H488A, and R648A presented partial infec-
tivity losses of the low-density viruses, resulting in sharper peaks of
1.10 g/ml (Fig. 7B–E). However, basic- and DHVR1 mutants
exhibited a strong impairment in infectivity at lower densities.
Thus, most of the detectable infectivity of these mutants reflected
the virus particle types of intermediate density (Fig. 7F and 7G,
respectively). HCV RNA analysis of mutant viruses revealed a shift
of RNA-containing particles to higher densities for all mutants
(Fig. 7B–G) Interestingly, Huh-7.5 cells transfected with the E1AA
mutant, secreted non-infectious HCV-RNA containing structures
(Fig. 7H) albeit at low levels, representing a ,0.1–1% of total
HCV-RNA secreted particles when compared to WT.
HCV-associated lipoproteins protect viral cross-
neutralizing epitopes and promote SR-BI-dependent
entry
Initially, the specificity of commercial anti-LDL, anti-HDL and
anti-ApoE antibodies with respect to their neutralization potential
of WT Luc-Jc1 viruses was analyzed (Fig. S4). The half maximal
inhibitory concentration (IC50) was ,0.54 mg/ml and ,8.09 mg/
ml for the anti-LDL and anti-HDL antibodies respectively, while
for the anti-ApoE the half maximal inhibitory dilution (ID50) was
,1:1,400. To clarify the mechanism underlying WT virus
protection from patient IgG, density fractions of WT viruses were
neutralized with IgG prior to infection. As shown in Figure 8A,
low-density particles were partially protected, while medium or
high density particles were potently neutralized, suggesting that
lipoproteins protected conserved viral cross-neutralizing epitopes.
Conversely, low-density particles were much more prone to anti-
SR-BI, anti-HDL and anti-LDL neutralization (Fig. 8B), indicat-
Figure 3. Effects of alanine substitutions for E2 basic amino acids on HCVcc infectivity, heparin neutralization, core release and
anti-ApoE inhibition. (A) HCVcc infectivity of Luc-Jc1 WT or mutants. Infectivity of each mutant is expressed as a percentage of the infectivity level
observed for the WT. The cut-off was set according to the infectivity observed for the E1AA mutant. Values shown represent the mean for three
assays (6 SD). Columns next to infectivity rates represent percentage (%) of E2 protein immunoprecipitated (shown in Fig. 2) and core supernatant
release relative to WT virus. (B) Huh-7.5 cells were infected with Luc-Jc1 WT or with the indicated E2 mutant viruses in the presence of GAG
antagonists (chondroitin sulfate or heparin, 200 mg/ml). The heparin neutralization scale was set relative to chondroitin sulfate neutralization. (C & D)
Dose-dependent inhibition of mutants entry by anti-ApoE. Infections were performed with WT or mutant viruses as follows: viruses were pre-
incubated with anti-ApoE antibodies at the given concentrations and then added to the cells. Results are drawn from a representative experiment of
three independent experiments. All points represent the mean of duplicate infections measured in duplicate (n = 4, 6 SD).a NA, not applicable.
doi:10.1371/journal.pone.0052651.g003
Figure 4. Dose-dependent inhibition of mutants entry by anti-CD81 antibodies. Huh-7.5 cells were infected with Luc-Jc1 WT or with the
indicated E2 mutant viruses as follows: viruses were added directly to the cells in the presence of anti-CD81 antibodies (clone JS81 or 1D6, A & B or C
& D, respectively). Results are drawn from a representative experiment of three independent experiments. All points represent the mean of duplicate
infections measured in duplicate (n = 4, 6 SD).
doi:10.1371/journal.pone.0052651.g004
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ing that HCV-associated lipoproteins, rather than the virus itself,
interact with this viral receptor. Surprisingly, anti-ApoE antibodies
neutralized all WT fractions to the same extent, similar to anti-
CD81 neutralizations (Fig. 8A and 8B).These results suggest that
CD81 receptor usage is indispensable by all fractions and
regardless the ApoE-associated amount to HCV, inhibition by
anti-ApoE antibodies is highly robust. Our efforts to analyze the
ApoE-associated amounts with respect to HCV density fractions
was not successful because of the adequate expression and
secretion of ApoE due to the cell metabolism: naı¨ve Huh-7.5 cells
secret similar ApoE amounts to Huh-7.5 cells as deduced by ApoE
western blot analysis in density fractions. (Fig. S5B)
Discussion
HS or other GAGs are used as receptors in the entry process of
various members of the Flaviviridae family: dengue fever [39],
classical swine fever (CSF) [40], and tick-borne encephalitis (TBE)
[41]. Virus-GAGs interactions are mainly electrostatic and occur
when the basic residues of the virus glycoproteins interact with
negatively charged sulfated chains of the GAGs. In order to
examine the role of the envelope glycoprotein E2 conserved basic
amino acids, we generated a panel of alanine mutants for the in
vitro infectious chimeric virus Jc1 (Table 1). These changes did not
have any effect on virus replication. Initially, we analyzed E2
mutant conformation by immunoprecipitation and western blot
with E2-specific antibodies. Three mutants (H617A, R657A and
R659A) were not immunoprecipitated by this method suggesting
that significant conformational changes are associated with the
alanine mutations. These mutants did not also secrete infectious
viruses and therefore were not analyzed further. For all other
mutants (except the H488A), E2 expression and conformation
remained at levels comparable to the WT virus. Interestingly, the
basic- mutant, which harbours the maximum change in positive
charge, did not demonstrate conformational change. Although we
tried hard to analyze E1E2 heterodimerization, we failed to
identify a suitable anti-E1 antibody for the Jc1 isolate. Further
addressing of E2 conformation would have been interesting but
outside the scope of this article.
HCVcc of the JFH-1 isolate (genotype 2a) interacts with heparin
and it can be precipitated in a heparin-pulldown assay [42].
Although we did not provide direct evidence for HCV-heparin
interactions, we identified two predominant positively-charged
residues (H386 and R408) of the HVR1 and the highly conserved
H488 and R648 amino acids in the putative GAG-binding motifs
described by Olenina et. al, which are implicated in a heparin-
resistance phenotype. Furthermore, our anti-ApoE neutralizations
suggest that all mutants still carry ApoE and imply that the
heparin-resistance phenotype is rather due to loss of direct E2-
heparin and not to HCV-ApoE-heparin interactions.
Figure 5. Dose-dependent inhibition of alanine mutants by anti-SR-BI and silencing of SR-BI. Huh-7.5 cells were infected with Luc-Jc1 WT
or with the indicated E2 mutant viruses as follows: (A and B): in the presence of anti-SR-BI antibodies at the given concentrations. (C) Huh-7.5 cells
were transfected 48 h prior to infection with control (scrambled) or SR-BI-specific siRNAs. Results are drawn from a representative experiment of three
independent experiments. All points represent the mean of duplicate infections measured in duplicate (n = 4, 6 SD).
doi:10.1371/journal.pone.0052651.g005
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Using serum-derived HCV, it has been suggested that the virus
associated ApoB-containing lipoproteins rather than the E2
interact with SR-BI [17]. In our analyses, we used the anti-SR-
BI monoclonal antibody C167, which not only prevents HDL
binding to SR-BI, but also inhibits SR-BI-mediated cholesterol
efflux. As shown in Figure 8A, our data strongly support this
hypothesis: viral particles of low density were neutralized by anti-
SR-BI, anti-LDL and anti-HDL antibodies. Furthermore, we
demonstrate that a mutant virus lacking basic residues in the
HVR1 was able to gain entry in an anti-SR-BI-independent
fashion. This mechanism was additive and dependent upon the
positive charge of HVR1. Strikingly, we inhibited DHVR1 mutant
entry, albeit up to only ,80%, while inhibition of WT was almost
complete. Bankwitz et al. [22], were not able to inhibit DHVR1
viruses with polyclonal anti-SR-BI IgG. The lower inhibition
potency of these polyclonal antibodies compared to the monoclo-
nal C167 antibodies (Fig. S2), may explain this discrepancy. Our
SR-BI knockdown studies were totally in line with the anti-SR-BI
neutralization studies. These findings suggest an exclusion of SR-
BI receptor for the basic- mutant entry. HVR1 has been also
implicated in the SR-BI-mediated entry [22]. However, our results
concerning DHVR1 neutralizations and entry inhibitions by SR-
BI knockdown suggest that E2-SR-BI interaction is complex and
cannot be restricted to HVR1.
The confirmed epitope of the A3RA antibody is formed by the
three segments spanning amino acids 396–424, 436–447, and
523–540 [32]; the first segment also overlaps with the HVR1
region (aa 384–410). Mutants R408A, basic- and DHVR1 were
effectively neutralized at low doses and H386A presented a similar
phenotype at higher doses, suggesting that the absence of HVR1
(or its positive charge) led to the antigenic exposure of the other
two segments. Consistent with these observations, our results also
underscore the important properties of basic residues about
protection against neutralizing antibodies. Cross-neutralization of
WT HCVcc by patient-derived IgG was limited, but much more
efficient when the basic amino acids of HVR1 were mutated or
when the HVR1 was absent.
HCV particles carrying the H488A or the R648A mutations, or
lacking basic amino acids in the HVR1 or the HVR1 itself,
differed from WT in the following regards: the very low-density
range WT particles were infectious; however, infectivity capacities
of H386A, R408A, H488A and R648A mutants were noted
primarily in the intermediate densities and for mutants basic- and
DHVR1 only in the intermediate and high densities. In vivo, the
variable densities of HCV particles have been attributed to
differential associations with lipoproteins and antibodies [19].
HCVcc also associates with lipoproteins, thus exhibiting a
heterogeneous density [11,33]. Our data suggest that the positive
charge of HVR1, as well as those charges of the highly conserved
H488 and R648, is involved in HCV-lipoprotein interactions.
Moreover, the resistance of the basic- mutant to anti-SR-BI
inhibition further supports our hypothesis that virus-associated
lipoproteins, rather than E2, interact with SR-BI. Furthermore,
our observations are consistent with a previous study demonstrat-
ing that HDL is a serum factor that attenuates neutralization of
HCVpp or HCVcc [21] by antiviral antibodies in a SR-BI
Figure 6. Dose-dependent inhibition of alanine mutants by conformational anti-E2 AR3A antibodies and patient-derived IgG. Huh-
7.5 cells were infected with Luc-Jc1 WT or with the indicated E2 mutant viruses as follows: viruses were with pre-incubated with anti-E2 AR3A
antibodies (A & B) or patient-derived IgG (C & D), at the given concentrations. Results are drawn from a representative experiment of three
independent experiments. All points represent the mean of duplicate infections measured in duplicate (n = 4, 6 SD).
doi:10.1371/journal.pone.0052651.g006
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Figure 7. Buoyant density infectivity and RNA of WT and mutant viruses. The indicated viruses were resolved using an iodixanol step
gradient. For each fraction HCV infectivity in Huh-7.5 cells and RNA (RT-qPCR) were determined. Values are plotted against the density of the
respective fraction. The infectivity is expressed as a percentage of the total infectivity obtained from all fractions. All points represent the mean of
duplicate infections measured in duplicate (n = 4, 6 SD). Results are drawn from a representative experiment of two independent experiments.
doi:10.1371/journal.pone.0052651.g007
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dependent manner. Here we demonstrate that mutants resistant to
anti-SR-BI inhibition were at the same time more sensitive to anti-
E2 neutralization. Based on our results with regard to WT viruses
shown in Figure 8B, we strongly contend that the viral-associated
lipoproteins are the key partner for all of these interactions and
their subsequent effects. These findings indicate that there exists
some interplay between SR-BI-HCV (and its lipoproteins) and
neutralizing antibodies
Finally, our data could provide valuable information for the
design and development of HCV entry inhibitors. Studies in uPA-
SCID mice have shown that HCV infection can be prevented in
vivo by blocking the CD81 or the SR-BI receptors with the
monoclonal antibodies JS-81 or novel SR-BI-specific antibodies,
respectively [43,44]. Although a HCV CD81-escape variant has
not been ever reported, CD81 is not involved in direct cell-to-cell
transmission. Furthermore, as we report here SR-BI-independent
variants, our results are critical for the design of any HCV
preventing strategy based on SR-BI [44]. A more favourable
approach could be therefore a combination therapy, targeting
both HCV receptor(s) and viral envelope protein(s).
Supporting Information
Information S1 A detailed list of antibodies used in this
study and protocols for site-directed mutagenesis, flow
cytometry and HCV cell culture replication kinetics
determination are provided in this section.
(DOC)
Figure S1 Effect of E2 mutants on HCV replication and
virus particle production. (A) Huh-7.5 cells were electropo-
rated with RNAs of Luc-Jc1 variants specified at the bottom.
Luciferase activity was measured at the indicated time points and
is expressed relative to RLUs obtained 4 h post transfection. Each
bar present the mean of duplicate wells measured in duplicate with
standard deviation (n = 4, 6 SD). (B) Huh-7.5 cells were
electroporated with RNAs of Jc1 variants specified at bottom.
72 h post electroporation, virus titers were measured by TCID50
in the supernatant (extracellular infectivity) or within the cells after
3 rounds of freeze-and-thaw (intracellular infectivity). Results are
drawn from a representative experiment of three independent
experiments and are expressed as a percentage of total infectivity
(intra- and extracellular) with standard deviations.
(TIF)
Figure S2 Inhibition of mutants entry by anti-SR-BI
antibodies. Huh-7.5 cells were infected with WT, ‘‘basic-’’, or
DHVR1 viruses in the presence of anti-SR-BI antibodies (human
monoclonal C167 or rat polyclonal anti-SR-BI). Results are
expressed relative to control inhibitions with human or rat IgGs
for the C167 or the rat anti-SR-BI, respectively. Results are drawn
from a representative experiment of three independent experi-
ments. All points represent the mean of duplicate infections
measured in duplicate with standard deviations (n = 4, 6 SD).
(TIF)
Figure S3 Expression of SR-BI on the surface of Huh-7.5
cells. SR-BI expression was analyzed 48 h post-transfection with
control or SR-BI-specific siRNAs. Cells were stained by using SR-
BI-specific (C167) antibodies and secondary antibodies conjugated
with Alexa FluorH 488. Gray profiles represent cells that were
stained only with the secondary antibodies. MFI: Mean fluores-
cence intensity.
(TIF)
Figure S4 Specificity evaluation of anti-LDL, anti-HDL
and anti-ApoE against WT Luc-Jc1 viruses. Luc-Jc1 viruses
were pre-incubated 1 h at RT with anti-LDL, anti-HDL (A) or
anti-ApoE antibodies (B), at the given concentrations or dilutions,
respectively. Infections with pre-incubated viruses were performed
as described in the main text. Infectivity of each condition is
expressed as a percentage of the infectivity level observed for the
control antibodies. Results are drawn from a representative
experiment of three independent experiments. All points represent
the mean of duplicate infections measured in duplicate (n = 4, 6
SD).
(TIF)
Figure S5 ApoE and core detection in density fractions.
Huh-7.5 cells were electroporated with WT or with the indicated
E2 mutant viruses. 72 h post electroporation supernatants were
harvested and separated in an iodixanol density gradient.
Fractions of WT viruses were plotted for ApoE and core proteins
(A) while mutant viruses were plotted only for ApoE. Supernatant
Figure 8. Density fraction neutralization of WT viruses by patient IgG, anti-SR-BI, anti-CD81, anti-LDL and anti-HDL. WT viruses were
resolved using an iodixanol step gradient. (A) Infections of individual fractions in the presence of patient IgG, anti-SR-BI (C167) or anti-CD81 (JS-81).
(B) Similar infections as described in (A) were performed with pre-incubated viruses with anti-ApoE, anti-HDL or anti-LDL. All points represent the
mean of duplicate infections measured in duplicate (n = 4, 6 SD). Results are drawn from a representative experiment of two independent
experiments.
doi:10.1371/journal.pone.0052651.g008
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from mock electroporated cells served for detection of the ApoE
constitutive cell secretion.
(TIF)
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